Can you stay on a low dose of WEGOVY?
At 1.7 mg, yes: the label names it as a maintenance dosage alongside 2.4 mg, which is the one it recommends. Below that the doses are starting and escalation steps, and the label gives one reason to hold at any of them, which is not tolerating the next.1
On this page
What counts as a maintenance dose
The ladder has two kinds of rung. The first four are there to be climbed, and the last two are there to be stayed on:
The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.
So 1.7 mg is not a compromise the label disapproves of. It is one of the two doses it names, and the choice between them is written as a judgment rather than a rule:
Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1),Clinical Studies (14.2)].
What the label does not offer is a maintenance dose below 1.7 mg. The lower steps are named for what they are, a starting dosage and three escalation dosages, and the WEGOVY dose schedule has the weeks each one occupies, as the label's own table sets them out.
When the label says to move up, and when to wait
The schedule steps every four weeks: 0.25 mg for weeks 1 to 4, then 0.5, then 1, then 1.7 mg, with maintenance from week 17. The only brake the label builds in is tolerability:1
If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.
One delay moves everything after it by four weeks, so a schedule that runs longer than the chart is the chart being used rather than broken. A gap does the same thing harder: after two or more missed injections in a row, the label restarts the escalation at a lower dosage, which is set out on if you missed a semaglutide dose. When the side effects that trigger a hold tend to show up is on how long semaglutide side effects last.
What 1.7 mg measured against 2.4 mg
The label reports one trial that ran both maintenance doses side by side. Study 6 put 401 East Asian adults on 1.7 mg, 2.4 mg or placebo for 68 weeks.1
| Weekly dose | Average weight change | Lost at least 5% |
|---|---|---|
| 1.7 mg | −9.6% | 72.8% |
| 2.4 mg | −13.2% | 84% |
| Placebo | −2.1% | 19.4% |
WEGOVY prescribing information, section 14.2, Table 10 (label revised 6/2026). 401 adults in Japan and South Korea, a quarter of them with type 2 diabetes; 101 on 1.7 mg, 199 on 2.4 mg, 101 on placebo.
Read it both ways. The higher dose lost more, by about three and a half points of body weight. The lower one still lost four times what placebo did, and nearly three quarters of the people on it reached 5%. That is the trade the label hands to your prescriber, and it is a different trade for someone who cannot keep 2.4 mg down.
What the weeks look like on the recommended dose is on what the WEGOVY trials measured at each stage.
What people who cut back actually did
In the pooled analysis of the 2.4 mg trials, stomach side effects sent 12.5% of people to a lower dose or a temporary break, against 1.7% on placebo. Of those who did that, 74.0% finished the study on treatment. At the end, 60.2% of them were taking 1.7 mg or more and 36.7% were back on 2.4 mg.3
So stepping back is common, it is usually temporary, and most of the people who did it were still on the drug at the end. That is the closest thing to an answer the record has for the question behind this one, which is whether coming down means giving up.
What staying low does to the bill
Less than you would think. 41 of the 92 sellers priced here state that their figure does not change with the dose, so a lower dose usually buys the same monthly charge. The maker’s own tablet pricing runs the other way, rising with the dose: how much the WEGOVY pill costs has those figures. There are exceptions to flat-price marketing: the Mochi Health review explains its current dose-based compounded pricing. Medication choice and dose remain clinical decisions.
Questions
Can I stay on 1 mg instead of going up?
The label does not name 1 mg as a maintenance dosage for weight reduction; it is the third escalation step, with four weeks of its own. What the label does allow is delaying the next increase by four weeks when a dose is not tolerated, and that is a conversation with your prescriber rather than something to decide at home.
When should my WEGOVY dose go up?
On the label’s schedule, every four weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for 5 to 8, 1 mg for 9 to 12, 1.7 mg for 13 to 16, and maintenance from week 17. If a dose is not tolerated, the label says to consider delaying the increase by four weeks.
Will I lose less weight on 1.7 mg?
In the one trial that compared them, yes, and not by as much as people expect: 9.6% at week 68 on 1.7 mg against 13.2% on 2.4 mg, with 72.8% and 84% of each group losing at least 5%. That was 401 adults in Japan and South Korea, so it is one population rather than every population.
Is staying low the same as microdosing?
No. 1.7 mg is one of the two maintenance dosages in the label, and holding a step for tolerability is written into it. Microdosing describes doses below the approved ones, which no label carries.
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.